Fotios Polydoros - Dissemin

All papers authored by Fotios Polydoros

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2017 Fotios Polydoros

Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in Chronic Myeloid Leukaemia (CML): Year 2 results in the British DESTINY study

Upload

This paper was not found in any repository, but could be made available legally by the author.

A. R. Pettitt, N. Kalakonda, M. Bickerstaff, G. Menon, A. Schuh, S. E. Coupland, F. Wandroo, M. Oates, S. Rassam, Fotios Polydoros

, K. Lin, C. Pocock, S. Jenkins, D. Turner, A. S. Duncombe and 8 other authors

Effect of adding idelalisib to frontline ofatumumab plus either chlorambucil or bendamustine in less fit patients with CLL: preliminary results from the NCRI RIALTO trial

Upload

Fotios Polydoros

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study

Upload

2016 Richard E. Clark, Graeme Smith, Jane F. Apperley, Christopher Pocock, Jenny L. Byrne, Fotios Polydoros

, Stephen G. O'Brien, Tony Coffey, Letizia Foroni, Mhairi Copland

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Upload

Michael Bonello, Jayachandran Panicker, Fotis Polydoros

, Rhys Davies, Sundus Alusi

I28 Does age of onset affect the clinical phenotype and its progression in adult onset huntington’s disease? An observational five year follow up study

Upload

Fotios Polydoros

Final results of the NCRI CLL210 trial of Alemtuxumab, Dexamethasone and Lenalidomide in patients with high-risk CLL (ORIGINAL PROTOCOL)

Upload

Fotios Polydoros

De-escalation of Tyrosine Kinase Inhibitor therapy is safe in chronic myeloid leykaemia in durable molecular response (>= MR3 for >= 12 months): initial results in the British DESTINY study

Upload

Fotios Polydoros

De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: initial safety results from the DESTINY trial

Upload

Ilias P. Gomatos, Christopher Halloran, Paula Ghaneh, Michael Raraty, Fotis Polydoros

, Fiona Campbell, Jonathan Evans, Robert Sutton, Jo Garry, Philip Whelan, John P. Neoptolemos

Management and Outcome of 64 Patients with Pancreatic Serous Cystic Neoplasms

Upload

This paper is made freely available by the publisher.

Christopher M. Halloran, Kellie Platt, Abbie Gerard, Fotis Polydoros

, Derek A. O’Reilly, Dhanwant Gomez, Andrew Smith, John P. Neoptolemos

, Zahir Soonwalla, Mark Taylor, Jane M. Blazeby, Paula Ghaneh

PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial

Download from dx.doi.org

2015 Ilias P. Gomatos, Christopher M. Halloran, Paula Ghaneh, Michael G. T. Raraty, Fotis Polydoros

, Howard L. Smart, Jonathan C. Evans, R. Yagati-Satchidanand, Jo M. Garry, Philip A. Whelan, Faye E. Hughes, Robert Sutton, John P. Neoptolemos

Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis:

Upload

Fotios Polydoros

Second Generation Tyrosine Kinase Inhibitors Mitigate the High Risk of Disease Progression in Chronic Myeloid Leukaemia Patients With High Diagnostic Levels of CIP2A

Upload

Ilias Gomatos, Michael Raraty, Christopher Halloran, Howard Smart, Rajesh Yagati-Satchidanand, Jonathan Evans, Paula Ghaneh, Phil Whelan, Jo Garry, Robert Sutton, Fay Hughes, Fotis Polydoros

, John Neoptolemos

Improved outcomes following minimal access vs open pancreatic necrosectomy in 394 patients with severe necrotizing pancreatitis. Comparison of two time periods

Upload

C. M. Lucas, R. J. Harris, A. K. Holcroft, L. J. Scott, N. Carmell, E. McDonald, F. Polydoros

, R. E. Clark

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

Upload

2014 Fotios Polydoros

Management and Outcome of 64 Patients with Pancreatic Serous Cystadenomas

Upload

This paper is available in a repository.

2008 Diane Potvin, Charles E. DiLiberti, Donald J. Schuirmann, Walter W. Hauck, Alan F. Parr, Robert A. Smith, Fotios Polydoros

Sequential design approaches for bioequivalence studies with crossover designs

Download from www.researchgate.net

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Fotios Polydoros